Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

361 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-invasive diagnosis and follow-up of portal hypertension.
Thabut D, Weil D, Bouzbib C, Rudler M, Cassinotto C, Castéra L, Serste T, Oberti F, Ganne-Carrié N, de Lédinghen V, Bourlière M, Bureau C. Thabut D, et al. Among authors: bourliere m. Clin Res Hepatol Gastroenterol. 2022 Oct;46(8):101767. doi: 10.1016/j.clinre.2021.101767. Epub 2021 Jul 29. Clin Res Hepatol Gastroenterol. 2022. PMID: 34332128
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. Among authors: bourliere m. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
Poynard T, Halfon P, Castera L, Charlotte F, Le Bail B, Munteanu M, Messous D, Ratziu V, Benhamou Y, Bourlière M, De Ledinghen V; FibroPaca Group. Poynard T, et al. Among authors: bourliere m. Aliment Pharmacol Ther. 2007 Mar 15;25(6):733-9. doi: 10.1111/j.1365-2036.2007.03252.x. Aliment Pharmacol Ther. 2007. PMID: 17311607 Free article.
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F; Observational VHC4 Study Group. Roulot D, et al. Among authors: bourliere m. J Viral Hepat. 2007 Jul;14(7):460-7. doi: 10.1111/j.1365-2893.2006.00823.x. J Viral Hepat. 2007. PMID: 17576387
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Poynard T, et al. Among authors: bourliere m. BMC Gastroenterol. 2007 Oct 15;7:40. doi: 10.1186/1471-230X-7-40. BMC Gastroenterol. 2007. PMID: 17937811 Free PMC article.
Combining non-invasive methods for assessment of liver fibrosis.
Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Bourlière M, et al. Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):73-9. doi: 10.1016/S0399-8320(08)73996-4. Gastroenterol Clin Biol. 2008. PMID: 18973849 Free article.
361 results